Abstract：
Detection of bone marrow involvement (BMI) for patients with follicular lymphoma (FL) is of great significance for staging and treatment. The clinical value of positron emission tomography/computed tomography (PET/CT) in assessing BMI is still under debate and investigation. PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify studies evaluating PET/CT in detecting BMI in FL patients. Data extraction and quality evaluation were independently conducted by two reviewers, and nine eligible studies were selected as final quantitative analysis. Nine studies comprising 1119 FL patients were included. The pooled sensitivity was 0.67 (95% CI, 0.38-0.87), and the pooled specificity was 0.82 (95% CI, 0.75-0.87). The pooled positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 3.7 (95% CI, 2.1-6.3), 0.4 (95% CI, 0.18-0.91), and 9 (95% CI, 2-33), respectively. The area under the curve of PET/CT to detect BMI in FL patients was 0.83 (95% CI, 0.8-0.86). Current evidence suggests that PET/CT cannot replace bone marrow biopsy to detect BMI, but it is still of partial clinical significance for the prognosis of patients with follicular lymphoma.
摘要：
检测滤泡性淋巴瘤（FL）患者的骨髓受累（BMI）对分期和治疗具有重要意义。正电子发射断层扫描/计算机断层扫描（PET/CT）在评估BMI中的临床价值仍在辩论和研究中。PubMed,Embase,WebofScience,系统检索CochraneLibrary数据库,以确定评估PET/CT检测FL患者BMI的研究。数据提取和质量评价由两名评审员独立进行,选择9项符合条件的研究作为最终定量分析.包括1119名FL患者的9项研究。合并敏感性为0.67(95%CI，0.38-0.87)，合并特异性为0.82(95%CI,0.75-0.87).合并的正似然比，负似然比，诊断比值比为3.7（95%CI，2.1-6.3），0.4（95%CI，0.18-0.91），和9（95%CI，2-33），分别。PET/CT检测FL患者BMI的曲线下面积为0.83(95%CI,0.8-0.86)。目前的证据表明，PET/CT不能代替骨髓活检来检测BMI，但对滤泡性淋巴瘤患者的预后仍有部分临床意义。
